Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Infection.

Bezlotoxumab is marketed for the prevention of recurrent infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world.